Literature DB >> 16091292

Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Paola Cinque1, Arabella Bestetti, Roberta Marenzi, Serena Sala, Magnus Gisslen, Lars Hagberg, Richard W Price.   

Abstract

Interferon-gamma-inducible protein (IP-10 or CXCL10) is a potent chemoattractant and has been suggested to enhance retrovirus infection and mediate neuronal injury. In order to assess this chemokine in central nervous system (CNS) HIV infection, we measured the cerebrospinal fluid (CSF) and plasma concentrations of CXCL10 by immunoassay in samples derived from 97 HIV-infected subjects across a spectrum of immunological progression and CNS complications and from 16 HIV seronegative control subjects studied at three clinical centers between 1994 and 2001. We also examined changes in the CSF and plasma CXCL10 concentrations in 30 subjects starting and three stopping antiretroviral therapy. CSF CXCL10 concentrations: (1) correlated with CSF HIV RNA and white blood cell (WBC) counts, but not with blood CXCL10, HIV RNA, or CD4 counts; (2) were increased in subjects with primary and asymptomatic HIV infections and AIDS dementia complex, but less frequently in those with more advanced infection, with or without CNS opportunistic diseases except cytomegalovirus encephalitis; (3) decreased in subjects starting antiretroviral in association with decreases in CSF and plasma HIV RNA and CSF WBCs; and (4) conversely, increased in subjects stopping treatment in parallel with CSF HIV RNA and WBCs. These results confirm that CSF CXCL10 associates closely with both CSF HIV and WBCs and suggest that this chemokine may be both a response to and contributing determinant of local infection. High CSF levels may be useful in the diagnosis of ADC in subjects with advanced immunosuppression in whom CMV encephalitis has been ruled out, though this issue requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091292     DOI: 10.1016/j.jneuroim.2005.07.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  47 in total

1.  West Nile virus-induced neuroinflammation: glial infection and capsid protein-mediated neurovirulence.

Authors:  Guido van Marle; Joseph Antony; Heather Ostermann; Christopher Dunham; Tracey Hunt; William Halliday; Ferdinand Maingat; Matt D Urbanowski; Tom Hobman; James Peeling; Christopher Power
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.

Authors:  Lynn Pulliam; Hans Rempel; Bing Sun; Linda Abadjian; Cyrus Calosing; Dieter J Meyerhoff
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

3.  Chronic CXCL10 alters the level of activated ERK1/2 and transcriptional factors CREB and NF-kappaB in hippocampal neuronal cell culture.

Authors:  Hilda Bajova; Thomas E Nelson; Donna L Gruol
Journal:  J Neuroimmunol       Date:  2008-03-10       Impact factor: 3.478

4.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

Review 5.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

6.  Neuroinvasion of fluorescein-positive monocytes in acute simian immunodeficiency virus infection.

Authors:  Candice C Clay; Denise S Rodrigues; Yan S Ho; Beth A Fallert; Kim Janatpour; Todd A Reinhart; Ursula Esser
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

8.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria.

Authors:  Gabriele S V Campanella; Andrew M Tager; Joseph K El Khoury; Seddon Y Thomas; Tabitha A Abrazinski; Lindsay A Manice; Richard A Colvin; Andrew D Luster
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

10.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.